 Regulus Therapeutics Inc NASDAQ: RGLS has announced top-line results from the first cohort of patients n9 with Autosomal Dominant Polycystic Kidney Disease ADPKD in its ongoing Phase 1b trial of RGLS4326. The study evaluates the safety, pharmacokinetics, and effects on pharmacodynamic biomarkers of multiple doses of RGLS4326. 